SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community champions the "OG meme" narrative of Rage Comics, positioning it as a foundational meme reset for the current market cycle. The dedicated base actively builds an ecosystem with platforms like RageMaker and RageGames, expressing strong conviction and rallying fellow enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to persistent analyst downgrades and intense negative sentiment from a community frustrated by its valuation disconnect from market highs. Despite ongoing calls to replace management, many investors are keenly discussing the stock's "deep value" and recent AI-focused partnerships, creating a fierce debate about a potential rebound leading up to its anticipated earnings report.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

News of CME Group planning Cardano futures is driving significant conversation around $ADA, signaling potential institutional interest. However, community sentiment is sharply divided, with many predicting an imminent "parabolic" rally and "moonshot" from perceived oversold levels. This bullish conviction contrasts with a vocal segment labeling ADA a "scam" and forecasting further declines, often citing broader market anxieties and past performance.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as it unveils significant quantum computing advancements, including its Nighthawk processor, and strengthens its enterprise AI and hybrid cloud strategy through a major acquisition and collaboration with Cisco on quantum networking. The community highlights IBM's established position in cutting-edge technology and consistent analyst upgrades, seeing it as a compelling, undervalued leader in the evolving tech landscape.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as recent Phase 3 open-label data indicates an 80% recurrence reduction for its breast cancer vaccine, significantly de-risking the asset. Community discussion highlights a tightly held "micro-float" and persistent open-market share accumulation by the CEO, fueling aggressive short-squeeze narratives amidst high borrowing costs for short sellers. With key biotech conferences approaching, many anticipate potential strategic partnership or acquisition news, further elevating expectations for this oncology company.

SILVER is a crypto project that links traditional silver with digital assets. Each unit of SILVER is backed by an equal amount of $SILVER tokens, ensuring stable value and easy trading in a secure blockchain environment. With SILVER, users can convert real silver into digital assets and trade globally with low fees. Each $SILVER token is backed by actual silver, offering stability and reliability for investors to grow their wealth. SILVER is a crypto project that links traditional silver with digital assets. Each unit of SILVER is backed by an equal amount of $SILVER tokens, ensuring stable value and easy trading in a secure blockchain environment. With SILVER, users can convert real silver into digital assets and trade globally with low fees. Each $SILVER token is backed by actual silver, offering stability and reliability for investors to grow their wealth.

SILVER

Silver is seeing a significant price surge, fueling an active community debate around its sustainability. Many speculate on a potential short squeeze against institutional positions and a growing physical supply deficit, while others point to extreme momentum indicators and upcoming commodity index rebalancing as signals for an imminent pullback.

City Holding Co. is a financial holding company, which engages in the provision of financial and community banking services. Its products produced and services rendered by City National include Commercial Banking, Consumer Banking, Mortgage Banking, and Wealth Management and Trust Services. The company was founded on March 12, 1982 and is headquartered in Charleston, WV.

City Holding Co.

City Holding (CHCO) is actively discussed following its latest earnings report, where a slight miss on expectations is being weighed against management's positive outlook on fundamental strength and a recent acquisition. Community sentiment appears mixed, with some investors emphasizing the regional bank's consistent performance and dividend history, while others are noting recent insider selling and technical signals suggesting a downtrend. The conversation reflects ongoing evaluation of CHCO's strategic growth and resilience within the broader banking environment.

Marine Products Corp. engages in the design, manufacture, and sale of fiberglass powerboats through its subsidiary. Its products include Vortex, Robalo, and Chaparral. The company was founded on August 31, 2000 and is headquartered in Atlanta, GA.

Marine Products Corp

Marine Products Corp. is trending after recent financial results revealed a continued downturn across the marine industry, marked by significant declines in sales and earnings. The community is actively debating whether the company's sustained dividend payout reflects strategic capital preservation amidst challenges, or if it delays confronting persistent macro-economic headwinds like high inventory and interest rates. While management adjusts production conservatively, some investors point to strong fundamentals and anticipate a potential sector stabilization.

Covenant Logistics Group, Inc. is a holding company, which engages in the provision of freight and logistics services. It operates through the following segments: Highway Services and Dedicated Contract Services. The Highway Services Segment includes two separate service offerings: Expedited Services (Expedited) and Over-the-Road Services (OTR), both of which transport one-way freight over non-routine routes. The Dedicated Contract Services Segment provides similar transportation services, but does so pursuant to agreements whereby equipment available to a specific customer for shipments over particular routes at specified times. The company was founded by David Ray Parker in 1986 and is headquartered in Chattanooga, TN.

Covenant Logistics Group Inc - Ordinary Shares - Class A

$CVLG is trending amidst discussions about trucking market normalization and cost inflation, as well as analyst ratings. Community members are weighing the company's strategic moves, including its dedicated fleet and diversification into poultry and government transport. Recent risk factor updates and customer volume pressures are also being closely examined.

World Acceptance Corp. engages in the small-loan consumer finance business. It offers short-term small instalment, medium-term larger loans, related credit insurance, ancillary products and services to individuals. The firm also offers income tax return preparation services to customers. The company also markets computer software and related services to financial services companies through its subsidiary, ParaData Financial Systems. It operates in the following segments: Small Loans, Large Loans, and Tax Advance Loans. World Acceptance was founded in 1962 and is headquartered in Greenville, SC.

World Acceptance Corp.

World Acceptance Corp. (WRLD) is trending following a significant earnings beat, which has sparked a bullish sentiment among some investors. The community is actively discussing the company's operational focus on credit quality and strategic shift to medium-term loans, though some express caution regarding the consumer finance sector's resilience in the current economic landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Equity

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. It operates through the following geographical segments: Chinese Mainland, USA, and Other Regions. The company was founded by Yu Xia, Peng Zhang, Baiyong Li, and Zhongmin Wang in March 2012 and is headquartered in Zhongshan, China.

Current Price	$15.47
Prev Close	$15.50
Open	$15.53
Dividend Yield	0.00%
50-Day Moving Average	$14.93
Beta	0.00
Avg. Volume	949.64
PE Ratio	-118.36

52-Week High	$23.15
52-Week Low	$6.81
Market Capitalization	$14.23B
EPS (Annual)	-$0.084
Price to Book	15.44
Revenue Per Employee	$97,239.76
Enterprise Value/EBITDA	N/A

AKESF
Akeso Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKESF News

AKESFAkeso Inc